8 research outputs found
Erste Erfahrungen mit Tolvaptan in der Behandlung von Neugeborenen und Säuglingen mit „Capillary-Leak-Syndrom“ nach kardiochirurgischen Eingriffen
Postoperative fluid management in critically ill neonates and infants with capillary leak syndrome (CLS) and extensive volume overload after cardiac surgery on cardiopulmonary bypass is challenging. CLS is often resistant to conventional diuretic therapy, aggravating the course of weaning from invasive ventilation, increasing
length of stay on ICU and morbidity and mortality.
Tolvaptan (TLV, vasopressin type 2 receptor antagonist) was used as an additive diuretic in neonates and
infants with CLS after cardiac surgery. Retrospective analysis of 25 patients with CLS including preoperative and
postoperative parameters was performed. Multivariate regression analysis was performed to identify predictors for TLV response.
Multivariate analysis identified urinary output during 24 h after TLV administration and mean blood
pressure (BP) on day 2 of TLV treatment as predictors for TLV response (AUC = 0.956). Responder showed greater
weight reduction (p < 0.0001), earlier weaning from ventilator during TLV (p = 0.0421) and shorter time in the ICU after TLV treatment (p = 0.0155). Serum sodium and serum osmolality increased significantly over time in all patients treated with TLV. In neonates and infants with diuretic-refractory CLS after cardiac surgery, additional aquaretic therapy with TLV showed an increase in urinary output and reduction in bodyweight in patients classified as TLV responder.
Increase in urinary output and mean BP on day 2 of treatment were strong predictors for TLV response.Die Behandlung von kritisch kranken Neugeborenen und Säuglingen nach kardiochirurgischen Eingriffen ist herausfordernd. Ein postoperatives Problem stellt das Capillary-Leak-Syndrom dar, das mit generalisierten Ödemen, intravasaler Hypovolämie und einer Erhöhung der Mortalität und Morbidität einhergeht. Dieses Capillary-Leak-Syndrom spricht regelhaft nur unzureichend auf konventionelle Diuretika an.In dieser Arbeit werden erste Erfahrungen mit Tolvaptan (Vasopressin-2-Rezeptor-Antagonist)als alternativem Therapieversuch bei Neugeborenen und Säuglingen mit genannter Problematik beschrieben
First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery
Background: Postoperative fluid management in critically ill neonates and infants with capillary leak syndrome (CLS) and extensive volume overload after cardiac surgery on cardiopulmonary bypass is challenging. CLS is often resistant to conventional diuretic therapy, aggravating the course of weaning from invasive ventilation, increasing length of stay on ICU and morbidity and mortality.
Methods: Tolvaptan (TLV, vasopressin type 2 receptor antagonist) was used as an additive diuretic in neonates and infants with CLS after cardiac surgery. Retrospective analysis of 25 patients with CLS including preoperative and postoperative parameters was performed. Multivariate regression analysis was performed to identify predictors for TLV response.
Results: Multivariate analysis identified urinary output during 24 h after TLV administration and mean blood pressure (BP) on day 2 of TLV treatment as predictors for TLV response (AUC = 0.956). Responder showed greater weight reduction (p < 0.0001), earlier weaning from ventilator during TLV (p = 0.0421) and shorter time in the ICU after TLV treatment (p = 0.0155). Serum sodium and serum osmolality increased significantly over time in all patients treated with TLV.
Conclusion: In neonates and infants with diuretic-refractory CLS after cardiac surgery, additional aquaretic therapy with TLV showed an increase in urinary output and reduction in bodyweight in patients classified as TLV responder. Increase in urinary output and mean BP on day 2 of treatment were strong predictors for TLV response
First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.
Die Behandlung von kritisch kranken Neugeborenen und Säuglingen nach kardiochirurgischen Eingriffen ist herausfordernd. Ein postoperatives Problem stellt das "Capillary-Leak-Syndrom" dar, das mit generalisierten Ödemen, intravasaler Hypovolämie und einer Erhöhung der Mortalität und Morbidität einhergeht. Dieses "Capillary-Leak-Syndrom" spricht regelhaft nur unzureichend auf konventionelle Diuretika an.In dieser Arbeit werden erste Erfahrungen mit Tolvaptan (Vasopressin-2-Rezeptor-Antagonist)als alternativem Therapieversuch bei Neugeborenen und Säuglingen mit genannter Problematik beschrieben.Postoperative fluid management in critically ill neonates and infants with capillary leak syndrome (CLS) and extensive volume overload after cardiac surgery on cardiopulmonary bypass is challenging. CLS is often resistant to conventional diuretic therapy, aggravating the course of weaning from invasive ventilation, increasing
length of stay on ICU and morbidity and mortality.
Tolvaptan (TLV, vasopressin type 2 receptor antagonist) was used as an additive diuretic in neonates and
infants with CLS after cardiac surgery. Retrospective analysis of 25 patients with CLS including preoperative and
postoperative parameters was performed. Multivariate regression analysis was performed to identify predictors for TLV response.
Multivariate analysis identified urinary output during 24 h after TLV administration and mean blood
pressure (BP) on day 2 of TLV treatment as predictors for TLV response (AUC = 0.956). Responder showed greater
weight reduction (p < 0.0001), earlier weaning from ventilator during TLV (p = 0.0421) and shorter time in the ICU after TLV treatment (p = 0.0155). Serum sodium and serum osmolality increased significantly over time in all patients treated with TLV. In neonates and infants with diuretic-refractory CLS after cardiac surgery, additional aquaretic therapy with TLV showed an increase in urinary output and reduction in bodyweight in patients classified as TLV responder.
Increase in urinary output and mean BP on day 2 of treatment were strong predictors for TLV response
COVID-19 in German Competitive Sports: Protocol for a Prospective Multicenter Cohort Study (CoSmo-S)
Objective: It is unclear whether and to what extent COVID-19 infection poses health risks and a chronic impairment of performance in athletes. Identification of individual health risk is an important decision-making basis for managing the pandemic risk of infection with SARS-CoV-2 in sports and return to play (RTP). Methods: This study aims 1) to analyze the longitudinal rate of seroprevalence of SARS-CoV-2 in German athletes, 2) to assess health-related consequences in athletes infected with SARS-CoV-2, and 3) to reveal effects of the COVID-19 pandemic in general and of a cleared SARS-CoV-2 infection on exercise performance. CoSmo-S is a prospective observational multicenter study establishing two cohorts: 1) athletes diagnosed positive for COVID-19 (cohort 1) and 2) federal squad athletes who perform their annual sports medical preparticipation screening (cohort 2). Comprehensive diagnostics including physical examination, laboratory blood analyses and blood biobanking, resting and exercise electrocardiogram (ECG), echocardiography, spirometry and exercise testing added by questionnaires are conducted at baseline and follow-up. Results and Conclusion: We expect that the results obtained, will allow us to formulate recommendations regarding RTP on a more evidence-based level
COVID-19 in German Competitive Sports: Protocol for a Prospective Multicenter Cohort Study (CoSmo-S)
Objective: It is unclear whether and to what extent COVID-19 infection poses health risks
and a chronic impairment of performance in athletes. Identification of individual health risk
is an important decision-making basis for managing the pandemic risk of infection with
SARS-CoV-2 in sports and return to play (RTP).
Methods: This study aims 1) to analyze the longitudinal rate of seroprevalence of SARSCoV-
2 in German athletes, 2) to assess health-related consequences in athletes infected
with SARS-CoV-2, and 3) to reveal effects of the COVID-19 pandemic in general and of a
cleared SARS-CoV-2 infection on exercise performance. CoSmo-S is a prospective
observational multicenter study establishing two cohorts: 1) athletes diagnosed positive
for COVID-19 (cohort 1) and 2) federal squad athletes who perform their annual sports
medical preparticipation screening (cohort 2). Comprehensive diagnostics including physical examination, laboratory blood analyses and blood biobanking, resting and
exercise electrocardiogram (ECG), echocardiography, spirometry and exercise testing
added by questionnaires are conducted at baseline and follow-up.
Results and Conclusion: We expect that the results obtained, will allow us to formulate
recommendations regarding RTP on a more evidence-based level
COVID-19 in German Competitive Sports: Protocol for a Prospective Multicenter Cohort Study (CoSmo-S)
Objective: It is unclear whether and to what extent COVID-19 infection poses health risks
and a chronic impairment of performance in athletes. Identification of individual health risk
is an important decision-making basis for managing the pandemic risk of infection with
SARS-CoV-2 in sports and return to play (RTP).
Methods: This study aims 1) to analyze the longitudinal rate of seroprevalence of SARSCoV-
2 in German athletes, 2) to assess health-related consequences in athletes infected
with SARS-CoV-2, and 3) to reveal effects of the COVID-19 pandemic in general and of a
cleared SARS-CoV-2 infection on exercise performance. CoSmo-S is a prospective
observational multicenter study establishing two cohorts: 1) athletes diagnosed positive
for COVID-19 (cohort 1) and 2) federal squad athletes who perform their annual sports
medical preparticipation screening (cohort 2). Comprehensive diagnostics including physical examination, laboratory blood analyses and blood biobanking, resting and
exercise electrocardiogram (ECG), echocardiography, spirometry and exercise testing
added by questionnaires are conducted at baseline and follow-up.
Results and Conclusion: We expect that the results obtained, will allow us to formulate
recommendations regarding RTP on a more evidence-based level